Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling Elderly (UFMR-BE)

Longitudinal Study on Urinary Function and Multimorbidity Risks Among Beijing Community-dwelling Elderly UFMR-BCE Longitudinal Study

This study focuses on Beijing community residents aged 60 and above, aiming to understand how urinary function (like bladder or kidney function) and multiple health problems (such as high blood pressure, diabetes) affect each other as people age-since current studies often only look at single diseases and don't cover this group well. To join, participants need to be a 60+ Beijing community resident who can answer simple questions; those with serious mental illnesses or expected lifespan under 1 year can't take part. The study starts with a baseline check (asking about the participants' health, habits, doing blood/urine tests or urinary function assessments, and possibly collecting small blood/urine samples). After that, the investigators will follow up every 6-12 months (via phone or clinic to update health info) and repeat key checks yearly; people with lower cognitive ability will be checked every 3 months. The investigators will also record new illnesses, mobility issues (like falls), or death. The study has passed ethical review-participants will get clear info before joining, can quit anytime, and participants' data will stay private; participants will also get free health check reports and basic advice. For participants, this means regular health monitoring; for everyone, it'll help make tools to spot high-risk groups (like a community app), design better help (e.g., exercise plans), and push for yearly urinary health checks in communities.

Study Overview

• Status: Not yet recruiting
• Conditions: Cardiovascular Diseases; Overactive Bladder; Lower Urinary Tract Symptoms; Diabetes Mellitus; Metabolic Syndrome; Benign Prostatic Hyperplasia; Chronic Kidney Disease; Female Pelvic Floor Dysfunction

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Qing Yuan, Doctor of Medicine; Phone Number: 8618910980422; Email: qyuanmd@outlook.com

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100853
      • Chinese PLA General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

The study population is derived from community-dwelling elderly residents in Beijing. Specifically, it includes individuals aged 60 years and older who live permanently in Beijing's communities (not in hospitals, nursing homes, or other institutional care settings) and are able to participate in routine health assessments and follow-ups. This population covers a broad age spectrum, ranging from young elderly (60-69 years) to super-elderly (90 years and older), and reflects the general health and living characteristics of Beijing's community-residing elderly group.

Description

Inclusion Criteria:

• Age ≥ 60 years
• Permanent resident of the participating Beijing community
• Able to cooperate with and complete study questionnaires and related procedures

Exclusion Criteria:

• Severe mental illness that impairs ability to cooperate with the study
• End-stage disease (confirmed by clinical diagnosis)
• Clinically assessed life expectancy < 1 year

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Beijing Community Elderly; This is a single observational cohort (no intervention applied) consisting of Beijing community-dwelling residents aged ≥60 years who meet the study's eligibility criteria (inclusion: able to cooperate with questionnaires; exclusion: severe mental illness, end-stage disease, or expected lifespan <1 year). The cohort is established to prospectively track changes in urinary function (e.g., indicators of chronic kidney disease, overactive bladder, benign prostatic hyperplasia) and the occurrence/progression of multimorbidity (e.g., metabolic syndrome, cardiovascular diseases, diabetes) over time. It serves to analyze the dynamic association between age-related urinary function decline and multimorbidity, without implementing any experimental treatments or interventions-only collecting natural health data, biological samples, and follow-up outcomes (e.g., functional decline, disease diagnosis, death) as part of routine observation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annual Incidence of Age-Related Multimorbidity Associated with Urinary Function	This outcome measures the incidence of newly developed chronic multimorbidities closely linked to age-related urinary function changes, including metabolic syndrome, cardiovascular diseases, diabetes mellitus, and Alzheimer's disease. Diagnosis is confirmed by clinical diagnostic criteria (e.g., diabetes mellitus defined as fasting blood glucose ≥7.0 mmol/L; hypertension, a subtype of cardiovascular disease, defined as blood pressure ≥140/90 mmHg) combined with medical record review. It reflects the initial association between urinary function and systemic multimorbidity during the aging process. The unit of measurement is "incidence rate (%)".	Baseline (at enrollment), 12 months after enrollment (1st annual assessment), 24 months after enrollment (2nd annual assessment), through study completion (average follow-up duration: 3 years)
Annual Progression Rate of Age-Related Multimorbidity Associated with Urinary Function	This outcome measures the proportion of participants with pre-existing multimorbidities (as specified above) who experience disease deterioration during follow-up. Progression is confirmed by clinical examinations and medical record review, including escalation of disease severity (e.g., progression from grade 1 to grade 2 hypertension) or occurrence of complications (e.g., diabetic nephropathy). It reflects the interactive worsening trend between urinary function and multimorbidity with aging. The unit of measurement is "progression rate (%)".	Baseline (at enrollment), 12 months after enrollment (1st annual assessment), 24 months after enrollment (2nd annual assessment), through study completion (average follow-up duration: 3 years)
Annual Change in International Prostate Symptom Score (IPSS)	This outcome assesses the annual change in the severity of lower urinary tract symptoms (LUTS) using the standardized IPSS scale (range: 0-35 points). A higher score indicates more severe symptoms such as frequent urination, urgent urination, and dysuria. Participants complete the questionnaire under the guidance of trained healthcare professionals, and data are directly extracted from the scale results. It is a key indicator reflecting core urinary function symptoms. The unit of measurement is "change in score (points)".	Baseline (at enrollment), 12 months after enrollment (1st annual follow-up), 24 months after enrollment (2nd annual follow-up), through study completion (average follow-up duration: 3 years)
Annual Change in Maximum Urinary Flow Rate (Qmax)	This outcome measures the annual change in the maximum speed of urination, which directly reflects bladder contractile function and urinary tract patency. Qmax is measured using a uroflowmeter, with participants required to empty their bladders completely during the test; the device automatically records the maximum flow rate. The unit of measurement is "change in value (mL/s)".	Baseline (at enrollment), 12 months after enrollment (1st annual follow-up), 24 months after enrollment (2nd annual follow-up), through study completion (average follow-up duration: 3 years)
Annual Change in Post-Void Residual Urine Volume	This outcome assesses the annual change in the volume of urine remaining in the bladder after voiding, which reflects bladder emptying function. The measurement is performed by professional physicians using ultrasound, and results are reported in milliliters (mL). A volume >50 mL indicates bladder emptying dysfunction. The unit of measurement is "change in volume (mL)".	Baseline (at enrollment), 12 months after enrollment (1st annual follow-up), 24 months after enrollment (2nd annual follow-up), through study completion (average follow-up duration: 3 years)

Collaborators and Investigators

• Sponsor: Chinese PLA General Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2026
• Primary Completion (Estimated): August 31, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: December 4, 2025
• First Submitted That Met QC Criteria: January 13, 2026
• First Posted (Actual): January 22, 2026

Study Record Updates

• Last Update Posted (Actual): January 22, 2026
• Last Update Submitted That Met QC Criteria: January 13, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Multimorbidity; Urinary function; Longitudinal study; Beijing community-dwelling elderly; Age-related functional decline
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Endocrine System Diseases; Pathologic Processes; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Chronic Disease; Disease Attributes; Metabolic Diseases; Urological Manifestations; Glucose Metabolism Disorders; Renal Insufficiency; Insulin Resistance; Hyperinsulinism; Urinary Bladder Diseases; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Cardiovascular Diseases; Metabolic Syndrome; Prostatic Hyperplasia; Diabetes Mellitus; Renal Insufficiency, Chronic; Lower Urinary Tract Symptoms; Urinary Bladder, Overactive
• Other Study ID Numbers: UFMR-BE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

IPD Plan Description

This study implements a data management plan centered on privacy protection and regulatory compliance. Individual Participant Data (IPD), including participants' demographic details, health indicators, and biological sample data, is collected via standardized forms and stored in encrypted databases with access controls (e.g., role-based permission management).

IPD might not be shared primarily due to privacy protection requirements. IPD contains sensitive personal health information, which is strictly regulated by laws such as the Personal Information Protection Law and ethical review commitments. Sharing IPD would require explicit informed consent from each participant, and unauthorized sharing risks privacy leakage (e.g., medical history exposure leading to discrimination). Given the sensitivity of elderly participants' health data, non-sharing is adopted to avoid potential harms and ensure compliance.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No